1. Home
  2. LENZ vs EQ Comparison

LENZ vs EQ Comparison

Compare LENZ & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LENZ Therapeutics Inc.

LENZ

LENZ Therapeutics Inc.

N/A

Current Price

$4.04

Market Cap

106.8M

Sector

Health Care

ML Signal

N/A

Logo Equillium Inc.

EQ

Equillium Inc.

N/A

Current Price

$1.36

Market Cap

89.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LENZ
EQ
Founded
2019
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.8M
89.4M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
LENZ
EQ
Price
$4.04
$1.36
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
★ $14.83
$8.56
AVG Volume (30 Days)
★ 1.2M
317.8K
Earning Date
10-28-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
$19,088,000.00
★ $41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$125.50
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$1.16
52 Week High
$32.13
$6.20

Technical Indicators

Market Signals
Indicator
LENZ
EQ
Relative Strength Index (RSI) 57.53 44.23
Support Level $3.60 $1.24
Resistance Level $6.11 $1.51
Average True Range (ATR) 0.38 0.12
MACD 0.14 0.03
Stochastic Oscillator 77.71 43.18

Price Performance

Historical Comparison
LENZ
EQ

About LENZ LENZ Therapeutics Inc.

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: